"The increase in the size of the heart is transverse to various diseases. This molecule could be used in different diseases that damage it", is the doctor in charge of the investigation, María Paz Ocaranza.DRA-n1

In 2007, professionals in the Division of cardiovascular diseases of the Catholic University of Chile (UC) they began to investigate the effects of angiotensin 1-9, molecule present in the organism, biological property had not been described previously.

The experts of this project-academic UC and of the University of Chile, members of the Center for advanced studies of chronic diseases (ACCDiS )- they discovered that the molecule produced a decrease in the size of the heart, facing stress conditions.

Today, These results were known, the research team developed a treatment for high blood pressure, secondary cardiovascular and renal damage.

"The increase in the size of the heart is transverse to various diseases. This molecule could be used in different diseases that damage it", is the doctor in charge of the investigation, María Paz Ocaranza, and adds that in addition, produces a decrease of the pressure blood, Pathology affecting 26% of the global population.

Currently, the Studio is located in the phase of pre clinical trials. Finished once, the scientists plan to continue with the development of the product out of Chile, which comply with the standards required by the Food and Drug Adminsitration (FDA) and in five years, begin clinical studies, those approved by the entity international, they will allow to launch the first Chilean drug of this type.

Research, already patented in Germany, France, United Kingdom, Italy, Spain, United States and Chile, He has counted with the support of private, a Fondef $490 million, where Conicyt contributed 60% and recently, Global UC program, It allowed them to go to the Cambridge Innovation Center, USA, where will return in July to implement networking. 

Source:https://www.df.cl/noticias/empresas/innovacion-y-emprendimiento/investigadores-uc-desarrollan-droga-contra-el-dano-cardiovascular/2016-05-06/212329.html